Selected overall survival (OS) rates in patients with melanoma brain metastasis
| 6 months OS rate (deceased; at risk) | 12 months OS rate (deceased; at risk) | 24 months OS rate (deceased; at risk) | Median OS (months) | P value (log-rank test) | |
| Total patient cohort (n=450 pts) | 76.0% (92; 292) | 57.9% (150; 206) | 37.0%(191; 112) | ||
| First-line systemic therapy | |||||
| CTLA-4+PD-1 (n=175) PD-1 (n=161) BRAF+MEK (n=114) | 74.3% (35; 101) 75.9% (35; 110) 78.6% (22; 81) | 57.5% (51; 69) 61.9% (53; 86) 52.6% (46; 51) | 33.7% (61; 31) 44.3% (68; 54) 29.2% (62; 27) | nr 26.6 16.5 | p=0.037 |
| Symptomatic brain metastases | |||||
| No (n=291) Yes (n=118) | 80.5% (48; 198) 65.1% (37; 69) | 62.7% (84; 141) 45.0% (55; 45) | 43.1% (107; 81) 22.7% (68; 20) | 30.8 11.5 | p<0.001 |
| Radiotherapy of brain metastases | |||||
| None (n=147) Stereotactic (n=137) Conventional (n=135) | 65.5% (40; 76) 89.0% (13; 105) 69.7% (36; 83) | 45.5% (55; 46) 73.0% (30; 82) 51.3% (55; 58) | 25.6% (61; 21) 52.1% (45; 49) 33.3% (68; 34) | 19.5 36.4 17.0 | p<0.001 |
| Surgery of brain metastases | |||||
| No (n=340) Yes (n=110) | 72.0% (80; 206) 87.8% (12; 86) | 54.7% (119; 144) 66.3% (31; 62) | 33.6% (150; 76) 46.8% (41; 36) | 20.1 36.4 | p=0.031 |
| Second-line systemic therapy | |||||
| CTLA-4+PD-1 (n=56) PD-1 (n=43) BRAF+MEK (n=64) Others (n=36) | 58.8% (21; 30) 59.5% (15; 22) 84.5% (9; 49) 48.3% (15; 14) | 39.1% (28; 18) 41.2% (19; 15) 63.3% (18; 31) 28.6% (20; 8) | 27.3% (31; 13) 21.8% (25; 7) 26.5% (25; 9) 17.9% (23; 5) | 10.4 10.5 19.7 7.3 | p=0.010 |
P values from log-rank test comparing the median OS values; p<0.05 was considered significant.
NR, not reached.